These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 30602127)

  • 1. The emerging role for Cullin 4 family of E3 ligases in tumorigenesis.
    Cheng J; Guo J; North BJ; Tao K; Zhou P; Wei W
    Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):138-159. PubMed ID: 30602127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cereblon in hematologic malignancies.
    Fuchs O
    Blood Rev; 2023 Jan; 57():100994. PubMed ID: 35933246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cullin-RING Ligase 4 in Cancer: Structure, Functions, and Mechanisms.
    Cheng J; Bin X; Tang Z
    Biochim Biophys Acta Rev Cancer; 2024 Sep; 1879(5):189169. PubMed ID: 39117093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4
    Sievers QL; Gasser JA; Cowley GS; Fischer ES; Ebert BL
    Blood; 2018 Sep; 132(12):1293-1303. PubMed ID: 30042095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cullin 4-DCAF Proteins in Tumorigenesis.
    Zhou Z; Song X; Wavelet CM; Wan Y
    Adv Exp Med Biol; 2020; 1217():241-259. PubMed ID: 31898232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. USP15 antagonizes CRL4
    Nguyen TV
    Proc Natl Acad Sci U S A; 2021 Oct; 118(40):. PubMed ID: 34583995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role and mechanism of CRL4 E3 ubiquitin ligase in cancer and its potential therapy implications.
    Sang Y; Yan F; Ren X
    Oncotarget; 2015 Dec; 6(40):42590-602. PubMed ID: 26460955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonproteolytic K29-Linked Ubiquitination of the PB2 Replication Protein of Influenza A Viruses by Proviral Cullin 4-Based E3 Ligases.
    Karim M; Biquand E; Declercq M; Jacob Y; van der Werf S; Demeret C
    mBio; 2020 Apr; 11(2):. PubMed ID: 32265326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].
    Yu Q; Xiong X; Sun Y
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2020 May; 49(1):1-19. PubMed ID: 32621419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRL4
    Barankiewicz J; Salomon-Perzyński A; Misiewicz-Krzemińska I; Lech-Marańda E
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Degron Blocking Strategy Towards Improved CRL4
    Bouguenina H; Scarpino A; O'Hanlon JA; Warne J; Wang HZ; Wah Hak LC; Sadok A; McAndrew PC; Stubbs M; Pierrat OA; Hahner T; Cabry MP; Le Bihan YV; Mitsopoulos C; Sialana FJ; Roumeliotis TI; Burke R; van Montfort RLM; Choudhari J; Chopra R; Caldwell JJ; Collins I
    Chembiochem; 2023 Dec; 24(23):e202300351. PubMed ID: 37418539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Building ubiquitination machineries: E3 ligase multi-subunit assembly and substrate targeting by PROTACs and molecular glues.
    Ramachandran S; Ciulli A
    Curr Opin Struct Biol; 2021 Apr; 67():110-119. PubMed ID: 33271439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.
    Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH
    Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs.
    Lindner S; Steinebach C; Kehm H; Mangold M; Gütschow M; Krönke J
    J Vis Exp; 2019 May; (147):. PubMed ID: 31157769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
    Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
    Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of thalidomide and its derivatives.
    Ito T; Handa H
    Proc Jpn Acad Ser B Phys Biol Sci; 2020; 96(6):189-203. PubMed ID: 32522938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amyloid Precursor Protein (APP) May Act as a Substrate and a Recognition Unit for CRL4CRBN and Stub1 E3 Ligases Facilitating Ubiquitination of Proteins Involved in Presynaptic Functions and Neurodegeneration.
    Del Prete D; Rice RC; Rajadhyaksha AM; D'Adamio L
    J Biol Chem; 2016 Aug; 291(33):17209-27. PubMed ID: 27325702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
    Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
    FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CRL4
    Mohamed WI; Schenk AD; Kempf G; Cavadini S; Basters A; Potenza A; Abdul Rahman W; Rabl J; Reichermeier K; Thomä NH
    EMBO J; 2021 Nov; 40(22):e108008. PubMed ID: 34595758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.